Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

Summary

Abbott Laboratories NYSE: ABT gave the market what it wanted in its Q2 earnings report, affirming that the Exact Sciences acquisition was a good one. The critical takeaways are that comp growth is solid, the Exact Sciences business has traction, and the near-term margin impairment the acquisition brought is less than expected. Abbott Laboratories TodayABTAbbott Laboratories$99.00 +9.73 (+10.90%) As of 02:01 PM Eastern This is a fair market value price provided by Massive. Learn more.52-Week Range$81.97▼$137.49Dividend Yield2.55%P/E Ratio27.73Price Target$117.61 Looking forward, profitability metrics have improved, leading to improved guidance, strengthened market sentiment, and a robust rebound in the share price.Get Abbott Laboratories alerts:Sign Up The share price rebound is an operative factor in the second half of 2026. Abbott’s market was overly depressed, given its historical value and capacity for capital returns, signaling a buying opportunity for investors. The post-release surge not only confirms support at the existing lows but is also backed by MACD and stochastic signals, suggesting a full reversal is in play. The market completely misjudged the Exact Sciences deal, focusing too intently on near-term margin pressure and execution risk, rather than the long-term commercial impact on revenue, margins, and earnings. Abbott Laboratories Q2 Report a Balm for Frayed Investor NervesAbbott Laboratories' Q2 report is solid, with reported growth of 13% and organic growth of 4.8%. Strength was underpinned by Exact Sciences and the 42.3% increase in Diagnostic services it brought, aided by an 8.4% increase in Established Pharmaceuticals and a 7.9% increase in Medical Devices. Nutrition, among the smaller segments, declined by 3.1%. Regionally, strengths were seen domestically and abroad. Margin news was the catalyzing factor. The company’s margins contracted but less than expected, leaving gross margin, operating and net income above analysts' forecasts. The criti...